Still a Role for Second-line Chemoimmunotherapy in Chronic Lymphocytic Leukemia?

Overview

Journal Haematologica

Specialty Hematology

Date 2018 Jul 5

PMID 29970493

Authors

Jennifer R Brown

Affiliations

Soon will be listed here.

References

OBrien S, Furman R, Coutre S, Flinn I, Burger J, Blum K . Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018; 131(17):1910-1919. PMC: 5921964. DOI: 10.1182/blood-2017-10-810044. View

Fornecker L, Aurran-Schleinitz T, Michallet A, Cazin B, Guieze R, Dilhuydy M . Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience. Am J Hematol. 2015; 90(6):511-4. DOI: 10.1002/ajh.23999. View

Zelenetz A, Barrientos J, Brown J, Coiffier B, Delgado J, Egyed M . Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017; 18(3):297-311. PMC: 5589180. DOI: 10.1016/S1470-2045(16)30671-4. View

Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Santucci Silva R, Grosicki S . Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2015; 17(2):200-211. DOI: 10.1016/S1470-2045(15)00465-9. View

Fischer K, Bahlo J, Fink A, Goede V, Herling C, Cramer P . Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2015; 127(2):208-15. DOI: 10.1182/blood-2015-06-651125. View

Landau D, Tausch E, Taylor-Weiner A, Stewart C, Reiter J, Bahlo J . Mutations driving CLL and their evolution in progression and relapse. Nature. 2015; 526(7574):525-30. PMC: 4815041. DOI: 10.1038/nature15395. View

Gordon M, Churnetski M, Alqahtani H, Rivera X, Kittai A, Amrock S . Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer. 2018; 124(15):3192-3200. DOI: 10.1002/cncr.31554. View

Byrd J, Furman R, Coutre S, Flinn I, Burger J, Blum K . Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1):32-42. PMC: 3772525. DOI: 10.1056/NEJMoa1215637. View

Brown J, Hillmen P, OBrien S, Barrientos J, Reddy N, Coutre S . Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2017; 32(1):83-91. PMC: 5770586. DOI: 10.1038/leu.2017.175. View

10.

Mato A, Nabhan C, Thompson M, Lamanna N, Brander D, Hill B . Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018; 103(5):874-879. PMC: 5927982. DOI: 10.3324/haematol.2017.182907. View

11.

Thompson P, OBrien S, Wierda W, Ferrajoli A, Stingo F, Smith S . Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015; 121(20):3612-21. PMC: 4866653. DOI: 10.1002/cncr.29566. View

12.

Puente X, Bea S, Valdes-Mas R, Villamor N, Gutierrez-Abril J, Martin-Subero J . Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015; 526(7574):519-24. DOI: 10.1038/nature14666. View

13.

Burger J, Tedeschi A, Barr P, Robak T, Owen C, Ghia P . Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 373(25):2425-37. PMC: 4722809. DOI: 10.1056/NEJMoa1509388. View

14.

Seymour J, Kipps T, Eichhorst B, Hillmen P, DRozario J, Assouline S . Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018; 378(12):1107-1120. DOI: 10.1056/NEJMoa1713976. View

15.

Thompson P, Tam C, OBrien S, Wierda W, Stingo F, Plunkett W . Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2015; 127(3):303-9. PMC: 4760129. DOI: 10.1182/blood-2015-09-667675. View

16.

Byrd J, Brown J, OBrien S, Barrientos J, Kay N, Reddy N . Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371(3):213-23. PMC: 4134521. DOI: 10.1056/NEJMoa1400376. View

17.

Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer C . Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011; 29(26):3559-66. DOI: 10.1200/JCO.2010.33.8061. View

18.

Cuneo A, Follows G, Rigolin G, Piciocchi A, Tedeschi A, Trentin L . Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica. 2018; 103(7):1209-1217. PMC: 6029555. DOI: 10.3324/haematol.2018.189837. View

19.

Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A . Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015; 126(16):1921-4. PMC: 4743433. DOI: 10.1182/blood-2015-05-647925. View